my.chemeurope.com
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
11-22-2005: PLIVA d.d. announced that its partner on ondansetron hydrochloride (HCl) orally disintegrating tablets (ODT) in 4 mg and 8 mg strengths, Kali Laboratories, Inc. ("Kali"), a whollyowned subsidiary of Par Pharmaceutical Companies, Inc., has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for the product, and that it has been awarded 180 days of marketing exclusivity for being the first to file an ANDA containing a paragraph IV certification for the product.
Under the terms of the agreement between the two companies, PLIVA Inc., PLIVA's wholly owned
U.S. subsidiary, has exclusive rights to market, sell and distribute ondansetron HCl ODT in the U.S.
The product will be manufactured by Kali and the companies will split profits from the sales of the
product.
GlaxoSmithKline currently markets ondansetron HCl ODT under the brand name Zofran ODT®. The
product is used for the prevention of nausea and vomiting associated with emetogenic cancer
chemotherapy, certain radiotherapies, and the prevention of postoperative nausea and/or vomiting.
Annual US sales of Zofran ODT® are approximately USD 225m.
Kali and Pliva Inc. are currently involved in litigation with GlaxoSmithKline. In July 2005, the U.S.
District Court for the District of New Jersey issued a summary judgment ruling in GlaxoSmithKline's
favor. Kali and Pliva Inc. are appealing the decision.
Watchlist
This is where you can add this news to your personal favourites
Right first time: Pioneering new methods of drug manufacture
Engineers at the University of Leeds have developed a simple technology which can be used in existing chemical reactors to ensure "right first time" drug crystal formation. Ensuring drug crystals are formed correctly is crucial to their efficacy and the efficiency of pharmaceutical manufact ... more
PLIVA to File Lawsuit Against HANFA
PLIVA d.d. announced that it plans to file a lawsuit against the Croatian Financial Services Supervisory Agency (HANFA) with the Administrative Court of the Republic of Croatia, following the notification received on 22 January 2007 of HANFA's Ruling that PLIVA withheld price-sensitive info ... more
PLIVA Announces Changes in Management and Supervisory Boards
Barr Pharmaceuticals, Inc. and its newly acquired subsidiary PLIVA d.d. announced changes to the Management and Supervisory Boards of PLIVA d.d. The changes resulted from the meeting of PLIVA's Supervisory Board that was held on October 30, 2006 in Zagreb, Croatia. Following the successful ... more
A consortium of GlaxoSmithKline (GSK), Green Biologics and the Centre for Processing Innovation (CPI), led by Stratophase, is developing a cost-effective, multi-parametric sensor system for increasing the efficiency of high-value liquid based production processes. The £1.2m APPLES (Advance ... more
GlaxoSmithKline announces USD 1.65 billion of acquisition Reliant Pharmaceutical
Pronova BioPharma ASA notes the announcement of a proposed USD 1.65 billion acquisition between GlaxoSmithKline PLC and Reliant Pharmaceuticals, Inc. GlaxoSmithKline is one of the world`s leading research-based pharmaceutical and healthcare companies and its proposed acquisition of Reliant, ... more
Anacor Pharmaceuticals and GlaxoSmithKline announced that they have entered into a worldwide strategic alliance for the discovery, development and commercialization of novel medicines for viral and bacterial diseases. The collaboration provides GlaxoSmithKline access to Anacor's proprietary ... more
About CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2011 CHEMIE.DE Information Service GmbH, All rights reserved
